NCT03465891 is a Phase 2 clinical trial of atezolizumab in Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT03465891?

NCT03465891 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT03465891?

Interventions in NCT03465891: atezolizumab, Low- Dose, Local Radiotherapy.

Is NCT03465891 still recruiting?

NCT03465891 is currently terminated. Last updated 12 January 2021.

Are results published for NCT03465891?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-01-12 · How we verify

NCT03465891

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Terminated Phase 2 Results posted Last updated 12 January 2021

What this trial tests

Phase 2 trial testing atezolizumab in Lymphoma in 2 participants. Terminated before completion.

Timeline

9 March 2018

Primary endpoint
17 December 2019

17 December 2019

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	9 March 2018
Primary completion	17 December 2019
Estimated completion	17 December 2019
Sites	6 locations across United States

Drugs / interventions tested

atezolizumab (atezolizumab) — full drug profile →
Low- Dose, Local Radiotherapy

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the safety and effects of atezolizumab with low dose radiation on people with relapsed or refractory follicular lymphoma, In this study, the patient will get either atezolizumab with low dose radiation or, atezolizumab alone. To be better, the atezolizumab and low dose radiation should increase life by 1 year or more compared to the usual approach.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Radiotherapy as a New Player in Immuno-Oncology.
Wang SJ, Haffty B. · · 2018 · cited 19× · PMID 30558196 · DOI 10.3390/cancers10120515
Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.
Li Y, Zheng R, Pan B, Wang X, et al · · 2025 · cited 1× · PMID 41357215 · DOI 10.3389/fimmu.2025.1713199

Verify or expand the search:

Other trials of atezolizumab

Trials testing the same drug.

NCT07472517 — DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop · Phase 3 · not yet recruiting
NCT05733611 — RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC · Phase 2 · terminated
NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed
NCT04920981 — Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC · completed
NCT04471415 — Study to Investigate DRP-104 in Adults With Advanced Solid Tumors · Phase 1, PHASE2 · terminated

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03465891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 12 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03465891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing